Avantium IPO “Many Times Oversubscribed:” What Buyers Are So Excited About
Jim Lane In France, Avantium completed its highly-anticipated initial public offering, raising $109.5M (€103M) via the sale of 9,401,793 shares at $11.70 (€11) per share, giving the company a market capitalization reaches of $294M (€277M). Trading will begin on March 15th 2017 on Euronext Amsterdam and Euronext Bruxelles under the symbol AVTX. The Company anticipates to use €65-75 million of the net proceeds of the Offering for the funding of the Joint Venture, enabling it to construct and operate the reference plant for the commercialization of the YXY technology. The company’s first world-scale plant is a 50,000 tons...
BioAmber Goes Ballistic
Jim Lane Word arrived from Minnesota that BioAmber has signed a 210,000 ton per year take-or-pay contract for bio-based succinic acid with Vinmar International. Explaining why BioAmber (BIOA) stock shot up nearly 17% in today’s trading despite a global equities pullback that affected almost everyone else in industrial biotech. Under the terms of the 15-year agreement, Vinmar has committed to purchase and BioAmber Sarnia has committed to sell 10,000 tons of succinic acid per year from the 30,000 ton per year capacity plant that is currently under construction in Sarnia, Canada. Bottom line, BioAmber continues to roll and roll....
Gevo’s Glow
Specialty chemicals developer Gevo, Inc. (GEVO: Nasdaq) is celebrating a string of market wins for its renewable chemicals and fuels. Since its beginning thirteen years ago this month, Gevo has been doggedly perfecting its synthetic biology and chemical technologies and turning it into products that are in demand by consumers and industry. Last week shareholders were treated to an announcement by the U.S. Environmental Protection Agency (EPA) raising the amount of isobutanol for on-road use to 16% blend level from 12.5%. As a producer of renewable isobutanol Gevo will be a direct beneficiary of the EPA action. Following directly on the heels of that news,...
BioAmber Completes IPO
Jim Lane Raises $80M at $10 per share; becomes first new industrial biotech company to complete IPO in more than a year. What went right and how? Is the IPO window re-opening? In Minnesota, BioAmber announced the pricing of its initial public offering of 8 million units consisting of one share of common stock and one warrant to purchase half of one share of common stock at $10 per unit, before underwriting discounts and commissions. All units are being sold. BioAmber has granted the underwriters an option for 30 days to purchase up to an additional 1.2 million...
Biofuels & Biobased Earnings Roundup: Novozymes
by Jim Lane
The Top Line. In Denmark, Novozymes (Copenhagen:NZYM-B; OTC:NVZMY) reported 4% organic sales growth for the first half and a 5 percent jump in Q2 with bioenergy reporting a 14% jump. Overall, net profit grew 5% and the company affirmed its 2018 guidance. Sales dipped to DKK 7,018m from DKK 7,278m, and EBITDA was flat at DKK 2,464m, although we primarily attribute that to currency shifts.
The Big Highlights. Growth in Food & Beverages and Agriculture & Feed; Bioenergy particularly strong. Good ramp-up of recent product launches. +7% organic sales growth in emerging markets; Freshness & hygiene platform in Household Care developing according to...
Interview With Dan Oh, CEO Of Renewable Energy Group
Jim Lane Leading a series this week, “The Strategics Speak", in which we’ll look at what a number of major strategic investors see in the landscape relating to industrial, energy and agricultural investment, Biofuels Digest visited with Dan Oh, CEO of Renewable Energy Group (REGI), which has long been the US’s leading independent biodiesel producer but in recent years has steadily diversified and expanded operations. In many ways, REG is the entire industrial biotech business in a nutshelll. They’re fermentation (through REG Life Sciences), and thermocatalytic (through REG Geismar and their extensive biodiesel business). They use both...
Biofuels M&A: 2017 Review and Outlook
by Bruce Comer, Ocean Park Advisors
More industry players chose to develop and build new capacity rather than buy plants
The North American biofuels industry experienced the fewest merger and acquisition transactions in recent history in 2017. There were only six M&A transactions, with a total estimated value of more than $100 million. They involved eight plants with 297 million gallons per year (MGPY) of production capacity. Half of these deals were for non-operating plants. A fourth deal was for a sub-scale demonstration plant. Contributing to the limited deal flow, two historically active acquirers, Green Plains and REG, did not close...
Biofuels & Biobased Earnings Roundup: Amyris
by Jim Lane
The Top Line. In California, Amyris (AMRS) reported Q2 GAAP revenue for the second quarter of 2018 of $24.8 million, compared with $25.7 million for the second quarter of 2017. Grants and collaborations revenue was $11.4 million for the second quarter of 2018 compared with $10.3 million for the year-ago period. The company noted that Q2 revenue was $24.8 million compared with the same period in 2017 of $21.7 million when adjusted for the low margin product sales on contracts assigned to DSM (DSM.AS). This reflects 15% growth on an absolute basis. GAAP net loss for the first half was $89.1...
The Hocky-Stick Growth of Biobased Intermediates
Super-cali-thali-terpa-butyl-peta what? Jim Lane The new trend in biofuels is not a biofuel at all – it’s an (usually unpronounceable) intermediate that can be refined into an array of fuels, chemicals, flavors, fragrances, and construction or packaging materials. Ptera-buta-thalic-what? We can hardly pronounce them, but we sure need to know about them. Amyris (AMRS), KiOR (KIOR), Renmatix, Virdia, Blue Sugars, Proterro, Sucre Source, Sweetwater Energy, Genomatica – hot companies all, what do they have in common? Instead of making a finished end-product, they make an intermediate which is then upgraded to a finished product, typically...
Biobased and Biofuel Investments: A System
Jim Lane A Biofuels and Biobased investment primer: An 18-combination, 8-character system for classifying bio investments Here’s our investment primer on how to size up the risks and the rewards and tune them to meet your goals. And, a system for organizing opportunities. So, you’re thinking about investing in bio? Here’s the good news – you’re not alone. Here’s the bad news – you’re not alone. There are retail, private equity, hedge fund, sovereign wealth, strategic, grower, VC and institutional investors snooping around too, and making active investments. For one thing, carbon’s making a comeback as the...
BioAmber’s Sarnia Plant Operating At Commercial Scale
Jim Lane Ultra-secret yeast tech also exceeding expectations in yield, productivity and quality, BioAmber reports. Baby Sarnia checks in at 60 million pounds, no ounces, doing fine. In Canada, BioAmber’s (BIOA) Sarnia joint venture with Mitsui & Co. Ltd. has begun shipping bio-succinic acid to customers and is operating its manufacturing process at commercial scale, meeting a significant company milestone, the company said. Yeast biotechnology exceeds performance targets BioAmber has confirmed the performance of its proprietary yeast in the production fermenters in Sarnia. The fermentation performance achieved is significantly above the initial targets set for...
Spring Blossoms: Amyris First Quarter Earnings
Jim Lane Lily flowered tulip 'Maytime' photo by Tom Konrad In California, Amyris (AMRS) announced net income of $16.4M on revenues of $6.2M for Q1 2014, after reporting a $32.6M loss in Q1 2013 on revenues of $9.0M. The change in net income was primary due to a non-cash benefit relating to outstanding convertible notes, a result of a decrease in the Company’s stock price at 3/31/14 compared to the stock price at 12/31/13. In a release accompanying the results, the company highlighted that it: Achieved combined...
List of Biochemicals Stocks
Biochemicals stocks are publicly traded companies whose business involves using plant or animal based feedstocks (biomass) to create new chemicals or substitutes of existing petrochemicals, plastics, or other fossil fuel derived substances other than fuels.
This post was last updated on 7/9/2021.
Amyris (AMRS)
BioAmber (BIOA)
Bion Environmental Technologies (BNET)
Circa Group AS (CIRCA.OL)
Codexis (CDXS)
Corbion (CRBN.AS; CSNVY)
Danimer Scientific, Inc. (DNMR)
Eastman Chemical Company (EMN)
Global Bioenergies (ALGBE: EURONEXT)
Novozymes (Copenhagen:NZYM-B; OTC:NVZMY)
Royal DSM (DSM.AS; KDSKF; RDSMY)
SECOS Group (SES.AX)
If you know of any biochemicals stock that is not listed here and should be, please let us know by leaving a comment. Also for stocks in the list that you think should...
TerraVia: No Going Back
Jim Lane At the outset of his historic Conquest, Cortés gathered the men and burned the boats. As TerraVia jettisons its break-out industrial product line and completes the pivot to Food, what lies ahead in the New World? Gromeko: They’ve shot the Czar. And all his family. Oh, that’s a savage deed. What’s it for? Zhivago: It’s to show there’s no going back. Dr. Zhivago In California, TerraVia (TVIA) recorded a loss of $27.4M for Q2 2016 on revenues of $9.9M as the company made milestone announcements in its transition from industrials to nutrition including...
Living Endangeredly- Q2 Biobased Earnings Roundup
by Jim Lane
In hand we now have the latest earnings reports from what you might call the 8 Pathfinders – eight publicly traded stocks whose second quarter results offer insights into the health and performance of the advanced bioeconomy as 2019 heads towards its closing crescendos.
Our 8 Pathfinders – In the world of global renewable diesel at scale, Neste (Neste.HE); pure-play enzymes, Novozymes (NVMB); In pharma and synbio, Codexis (CDXS); as a hybrid play in advanced fuels, Aemetis (AMTX); in advanced marine and jet fuels, Gevo (GEVO); for biodiesel and hydrocarbons, Renewable Energy Group (REGI); in advanced began foods,...
Amyris Inks $100M+ Biofene Supply Pact
Jim Lane In California, the Eco-Emirs of Emeryville, Amyris (AMRS) executed a five year Biofene supply agreement with a global nutraceuticals company. Upping the ante from January This new, long-term agreement replaces the parties’ one-year purchase agreement, which was previously announced on January 4, 2016. More on that deal here. Under the new supply agreement, the mystery customer has agreed to a larger Biofene purchase in 2016 with an expected revenue contribution of approximately $9 million and to minimum annual purchase commitments in each of the remaining years of the agreement. In addition, under the new agreement, Amyris...
